Why BerGenBio’s Bemcentinib Will Kick-Off UK’s COVID-19 ACCORD Program
New Direction For Phase II Anticancer Agent
There is strong scientific rationale from US and UK research to support evaluating the selective AXL kinase inhibitor bemcentinib in the UK’s early-stage clinical study program, ACCORD, a new initiative to find potential COVID-19 therapies.
